Last updated: August 2, 2026
Synera is a prescription topical anesthetic system containing 70 mg of lidocaine and 70 mg of tetracaine. The heat-activated patch is used for local dermal anesthesia before venipuncture and superficial dermatologic procedures. Its commercial position is defined by convenience, rapid application, and a narrow clinical market rather than by broad pharmaceutical volume.
Public companies have not reported Synera-specific revenue, unit sales, or operating profit. The product’s financial trajectory therefore must be assessed through FDA status, market positioning, competitive substitution, reimbursement conditions, and commercial ownership rather than through disclosed segment-level revenue.
What is Synera and how does the drug work?
Synera is a single-use topical delivery system that combines lidocaine and tetracaine in a heat-generating patch. The product is applied to intact skin for approximately 20 to 30 minutes before a procedure. The patch produces local anesthesia without injection and without the longer application period commonly associated with topical anesthetic creams.
| Attribute |
Synera |
| Active ingredients |
Lidocaine 70 mg and tetracaine 70 mg |
| Dosage form |
Topical system, or medicated patch |
| FDA application |
NDA 021717 |
| Primary uses |
Venipuncture and superficial dermatologic procedures |
| Administration |
Topical application to intact skin |
| Typical application period |
Approximately 20 to 30 minutes |
| Product type |
Prescription local anesthetic |
| Biologic status |
Not a biologic; biosimilar pathway does not apply |
| Commercial model |
Prescription product sold through medical and pharmaceutical channels |
Synera’s value proposition is operational. It can reduce the need for injected local anesthetic and can fit into clinical workflows where a short preparation period is acceptable. Its limitations include single-use economics, restricted indications, potential skin reactions, and competition from lower-cost topical anesthetics.
The FDA label states that Synera is indicated for topical local anesthesia before venipuncture or superficial dermatological procedures in adults and children aged three years and older.[1]
What is the FDA regulatory status of Synera?
Synera received FDA approval under NDA 021717. It is a drug-device combination in which the patch delivers the active anesthetic ingredients through a heat-activated system.
The main regulatory factors are:
- Prescription-only status.
- Use on intact skin rather than open wounds or mucosal tissue.
- Age-specific labeling beginning at three years.
- Warnings related to methemoglobinemia, local skin reactions, allergic reactions, and excessive exposure to local anesthetics.
- Administration by trained clinical personnel or according to the approved label.
The product is not an injectable anesthetic, controlled substance, vaccine, or biologic. It therefore does not face the biosimilar competition that affects monoclonal antibodies and other biological products.
FDA regulatory risk is relatively low for the approved indications because Synera has an established label and long commercial history. The main regulatory risks are manufacturing consistency, device performance, labeling compliance, and postmarketing safety rather than clinical proof of a new mechanism.
What market does Synera compete in?
Synera competes in the topical local-anesthesia market. Its closest alternatives are EMLA cream, generic lidocaine-prilocaine products, lidocaine creams, lidocaine patches used outside their primary approved indications, and nonprescription topical anesthetics.
How does Synera compare with EMLA and generic topical anesthetics?
| Factor |
Synera |
EMLA and generic lidocaine-prilocaine creams |
| Delivery format |
Heat-activated patch |
Cream or topical emulsion |
| Application workflow |
Shorter preparation period |
Often requires longer dwell time and occlusion |
| Dosing control |
Unit-dose patch |
Measured or dispensed cream |
| Handling |
Clean, disposable patch |
Cream application and removal |
| Cost position |
Generally higher-cost format |
Usually lower-cost alternatives |
| Main advantage |
Convenience and workflow integration |
Price and broad availability |
| Main disadvantage |
Single-use product cost |
Longer preparation and variable application |
Synera has a stronger proposition in settings where staff time, cleanliness, and predictable application are important. It is less competitive when procurement departments prioritize acquisition cost or when procedures can be scheduled around a low-cost cream.
The product also competes indirectly with injected lidocaine. Injection provides deeper anesthesia and often has a lower material cost, but it introduces needle discomfort and requires a separate administration step.
What drives Synera demand?
Synera demand is linked to procedure volume rather than chronic disease prevalence. Key demand drivers include:
- Pediatric venipuncture and outpatient procedures.
- Dermatology clinics performing superficial procedures.
- Hospital protocols designed to reduce needle-related distress.
- Clinics that value standardized unit-dose products.
- Procedure centers where staff time has a measurable economic value.
Demand is more constrained in adult settings where clinicians can use injected lidocaine or inexpensive creams. Pediatric care provides a more favorable commercial environment because avoiding an anesthetic injection can improve patient acceptance and procedural efficiency.
The product’s addressable market is therefore narrower than the overall local-anesthetic market. Its growth depends on adoption within selected workflows, not on conversion of all topical-anesthetic users.
What is the financial trajectory for Synera?
Synera-specific financial results are not publicly disclosed in major public-company filings. There is no reliable public revenue series that supports a precise estimate of annual sales, profitability, or market share.
The commercial trajectory can be divided into four phases:
| Period |
Financial and market characteristics |
| Launch and adoption |
Premium pricing supported by product differentiation and convenience |
| Early expansion |
Adoption in pediatric, dermatology, and outpatient procedure settings |
| Maturity |
Competition from generic creams and institutional purchasing pressure |
| Current commercial phase |
Demand concentrated in specialized accounts, with growth dependent on distribution and formulary retention |
The product’s revenue profile is likely driven by repeat procedural use, hospital contracts, distributor access, and formulary placement. It is not driven by daily chronic therapy or large primary-care prescribing.
What affects Synera profitability?
Synera’s gross-margin profile depends on several factors:
- Patch manufacturing complexity.
- Device and drug-component quality controls.
- Packaging and single-use distribution.
- Contract manufacturing costs.
- Specialty pharmacy or medical-distribution discounts.
- Hospital group purchasing organization terms.
- Returns, expiration, and inventory management.
- Promotional spending directed toward clinicians.
A patch can command a premium over cream, but the patch format also carries higher manufacturing and packaging costs. Financial performance depends on whether the convenience premium exceeds those costs after distributor and institutional discounts.
How large is Synera’s revenue exposure?
Synera is unlikely to represent material revenue exposure for a diversified pharmaceutical company unless it is held by a small or specialty-focused manufacturer. Its clinical niche limits absolute sales potential, while its prescription status and unit-dose format support some pricing differentiation.
The principal commercial risks are:
- Substitution by generic lidocaine-prilocaine cream.
- Hospital purchasing policies that favor lower-cost alternatives.
- Loss of distribution coverage.
- Procedure-volume declines.
- Product discontinuation or supply interruptions.
- Reduced use of topical anesthesia in adult outpatient procedures.
The principal upside drivers are:
- Increased pediatric procedure volumes.
- Wider adoption in ambulatory surgery and dermatology.
- Better reimbursement or institutional purchasing support.
- Evidence showing reduced procedure time or improved patient experience.
- Expansion into additional superficial procedures, subject to FDA approval.
Without disclosed sales data, Synera should be valued as a niche branded product rather than as a high-growth pharmaceutical franchise.
What patents protect Synera?
Synera’s protection has historically depended on patents covering topical anesthetic delivery systems, patch construction, heat activation, and the formulation or use of lidocaine and tetracaine.
The commercial value of any remaining patent protection depends on:
- The specific patent claims.
- Orange Book listing status.
- Patent expiration and patent-term adjustment.
- Whether claims cover the active product or only selected manufacturing and delivery features.
- Whether an abbreviated new drug application can demonstrate bioequivalence to the patch.
- Device-related manufacturing complexity.
A generic cream is not necessarily a direct pharmaceutical equivalent to Synera’s patch. A competing patch would face more significant formulation, device, adhesion, heat-generation, dose-uniformity, and bioequivalence issues.
What is the Orange Book status of Synera?
Synera is associated with FDA NDA 021717. Orange Book treatment depends on the patents listed for the specific NDA and the current edition of the FDA publication. Any patent-based exclusivity analysis must distinguish between:
- Active patents listed against NDA 021717.
- Expired patents.
- Unlisted formulation or manufacturing patents.
- Device-related intellectual property that may not create Orange Book-listed pharmaceutical exclusivity.
The practical barrier to generic entry may therefore persist after core patent expiry if a competing manufacturer cannot efficiently reproduce the patch’s delivery performance.
When does Synera lose exclusivity?
Synera’s statutory market exclusivity is separate from patent protection. FDA approval does not by itself establish a permanent period of exclusivity. Any remaining protection depends on the applicable patents and the timing of generic competition.
For a product with an older NDA, the key commercial question is no longer the existence of initial approval exclusivity. It is whether a competitor can file an ANDA, address any listed patents through Paragraph IV certification, and demonstrate pharmaceutical equivalence or bioequivalence for the topical system.
Patent expiry does not guarantee immediate generic entry. A competitor must still solve:
- Patch adhesion.
- Heat activation.
- Drug release.
- Lidocaine and tetracaine content uniformity.
- Skin exposure and local tolerability.
- Packaging stability.
- Manufacturing scale-up.
Which companies are challenging Synera?
No major, publicly visible Paragraph IV litigation campaign against Synera is established in the core public record available for this analysis. The absence of prominent litigation does not establish that no ANDA activity exists. It indicates that Synera has not generated the level of generic litigation associated with high-revenue products such as blockbuster oral drugs or biologics.
Potential challengers would most likely include manufacturers with capabilities in:
- Topical semisolid and transdermal products.
- Drug-device combination products.
- Specialty generic manufacturing.
- Hospital and ambulatory-care distribution.
A generic entrant would probably target price-sensitive institutions first. A branded competitor would more likely compete through a cream, alternative patch, or procedural workflow product.
What formulation and manufacturing barriers affect generic entry?
Synera’s patch format creates more complex barriers than a conventional topical cream. The product combines pharmaceutical formulation with device engineering.
Important manufacturing controls include:
- Uniform loading of both active ingredients.
- Stable drug release during the labeled application period.
- Reliable heat generation.
- Patch adhesion without excessive skin irritation.
- Consistent temperature exposure.
- Packaging that preserves product performance.
- Reproducible performance across different skin types and ages.
These requirements can reduce the number of technically capable generic manufacturers. They also increase development costs and may lengthen the path from patent expiry to commercial launch.
What litigation and settlement agreements affect Synera?
No major publicly reported settlement agreement is identified as a central driver of Synera’s market position. The absence of a prominent settlement limits evidence for a near-term, date-certain generic launch.
If a future ANDA challenge were filed, relevant settlement terms could include:
- An agreed generic entry date.
- A license to certain patch technology.
- Restrictions on product distribution.
- Authorized-generic arrangements.
- Manufacturing or supply commitments.
Until such an agreement is publicly disclosed, Synera’s generic-entry timing cannot be treated as contractually fixed.
How does Synera compare with competing local anesthetics?
Synera has a differentiated delivery system but a limited use case.
| Product category |
Commercial strength |
Main weakness versus Synera |
| Generic lidocaine cream |
Low acquisition cost |
Less standardized workflow |
| EMLA cream |
Established clinical use |
Longer application period |
| Injectable lidocaine |
Strong anesthesia and low unit cost |
Needle administration |
| Vapocoolant spray |
Immediate cooling effect |
Shorter and different anesthetic effect |
| Synera |
Convenient patch-based delivery |
Higher product cost and narrower use |
Synera is best positioned where clinical workflow and patient acceptance justify a premium. It is less defensible in price-driven formularies.
What generic launch scenarios exist for Synera?
Three launch scenarios are commercially plausible:
Limited substitution
A small number of generic or alternative topical products enter selected hospital systems. Synera retains accounts that value the patch format, but pricing pressure increases.
Broad formulary substitution
A lower-cost equivalent or competing patch achieves sufficient distribution and displaces Synera in institutional accounts. This would create the highest revenue risk.
No direct patch substitute
Generic creams continue to pressure pricing, but no competitor reproduces the delivery system effectively. Synera remains a niche branded product with stable but limited demand.
The third scenario is more favorable for the incumbent but does not eliminate erosion from non-equivalent topical alternatives.
What is the investment and licensing outlook for Synera?
Synera is more suitable for specialty-product licensing than for a large-scale pharmaceutical acquisition thesis. Potential licensing value would depend on:
- Current commercial availability.
- Manufacturing transferability.
- Distribution reach.
- Product margin after discounts.
- Remaining intellectual-property life.
- Regulatory obligations.
- Evidence of repeat institutional demand.
A licensee would likely seek rights bundled with manufacturing know-how, regulatory files, trademarks, and established distributor relationships. A transaction based only on the brand, without secure supply and channel access, would carry limited strategic value.
Key Takeaways
- Synera is a prescription lidocaine/tetracaine heat-activated topical patch.
- Its commercial niche is pediatric venipuncture, dermatology, and selected outpatient procedures.
- The product competes mainly with EMLA, generic lidocaine-prilocaine creams, injectable lidocaine, and other topical anesthetics.
- Synera’s main advantage is workflow convenience; its main weakness is higher unit cost.
- Synera-specific revenue, profit, and market-share data are not publicly disclosed.
- The product is not subject to biosimilar competition.
- Generic entry is constrained by the drug-device combination, patch performance, manufacturing controls, and bioequivalence requirements.
- No major public Paragraph IV litigation or settlement is identified as a current commercial driver.
- The asset has niche licensing value but limited evidence of blockbuster-scale financial potential.
- Long-term revenue depends more on formulary retention and manufacturing continuity than on broad therapeutic expansion.
FAQs
Is Synera still commercially available?
Synera has an FDA-approved product history under NDA 021717, but commercial availability depends on the current manufacturer, distributor inventory, and market supply status.
Is Synera equivalent to EMLA cream?
No. Both provide topical local anesthesia, but Synera uses a heat-activated patch containing lidocaine and tetracaine, while EMLA uses a lidocaine-prilocaine cream formulation.
Can a generic manufacturer copy Synera as a cream?
A cream would not automatically be an equivalent copy of Synera’s patch. A direct generic competitor would need to satisfy FDA requirements applicable to the product’s dosage form, delivery performance, active ingredients, and bioequivalence.
Does Synera have biosimilar risk?
No. Synera is a small-molecule topical drug-device product, not a biologic. Competition would arise through generic or alternative topical-anesthetic pathways.
What is the main commercial risk for Synera?
The main risk is substitution by lower-cost topical anesthetics, particularly generic lidocaine-prilocaine cream, combined with institutional pressure to reduce single-use product costs.
References
-
U.S. Food and Drug Administration. (2005). Synera prescribing information: Lidocaine 70 mg and tetracaine 70 mg topical system. FDA.
-
National Library of Medicine. (n.d.). Synera: Lidocaine and tetracaine topical system. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.fda.gov/drugsatfda
-
U.S. Food and Drug Administration. (n.d.). Electronic Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
